Evidence map›Paper›PMID 41770489›Full record

ReviewDrug safety2026

Genetically Informed Research Designs in Perinatal Pharmacoepidemiology: A Methodological Overview.

Alexis C Carson, Mahmoud Zidan, Emilie Willoch Olstad, Kristina Gervin, Tessel E Galesloot, Iris Scholte, Eivind Ystrøm, Hedvig Nordeng, Marleen M H J van Gelder

Abstract readReview
In one paragraph

Review in Drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alexis C Carson *PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0009-0003-6883-7018
Mahmoud Zidan *PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0009-0007-6881-5627
Emilie Willoch OlstadPharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0002-9578-8886
Kristina GervinPharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0002-9851-1890
Tessel E GaleslootIQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0002-2717-3679
Iris ScholteIQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands.
Eivind YstrømUiO:RealArt Convergence Environment, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0003-4390-6171
Hedvig NordengPharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0001-6361-2918
Marleen M H J van GelderPharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway. marleen.vangelder@radboudumc.nl.ORCID http://orcid.org/0000-0003-4853-4434

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the widespread use of medications during pregnancy, ethical and methodological barriers to clinical trials make observational studies necessary for evaluating medication safety in this population. Observational studies are prone to biases that often limit their validity due to the lack of randomization; integrating genetic information through discordant sibling designs, polygenic scores, and Mendelian randomization can address several confounding issues. However, application of these three approaches in perinatal pharmacoepidemiology has been limited. Complementing traditional designs with these genetically informed research designs can tackle common biases and strengthen causal inference. This paper focuses on applying genetically informed research designs to child outcomes in perinatal pharmacoepidemiology by reviewing various methods, discussing their strengths and limitations, and examining their application to date, as well as considerations for implementing them in future research. Such considerations include the availability of genetic data, the complexity of integrating genetic data with existing epidemiological data, and selection of appropriate genetic instruments for analyses. Incorporating causal inference in perinatal pharmacoepidemiology can ultimately contribute to enhancing safe medication use during pregnancy.

Indexed as

Drug-Related Side Effects and Adverse ReactionsPharmacoepidemiologyResearch DesignFemaleHumansPharmacogeneticsPregnancy

Identifiers

PMID41770489
PMCPMC13263198

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.